Stocks & ETFs

Latest News

Blogs & Articles

Stratagy Backtesting

Portfolio Analyser

Price Analyser

Compare Stocks

Stock & ETF Screener

Pricing

About The Company

Market Cap

915.42 Million HKD

Sector

Healthcare

Website

https://www.zeus.cn

Description

Zhongzhi Pharmaceutical Holdings Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China.

Read More

Overview

Value

67

Growth

20

Health

45

Management

37

Analyst Opinion

86

Total

51

All Scores Out Of 100

Best Features

  • Earnings growth has improved recently
  • Has a low level of debt
  • Price-to-earnings ratio of 7.2 is lower than the market average (19.6x)
  • Has a margin-of-safety above fair value
  • Liked by analysts

Risk Factors

  • Poor earnings and cashflow growth

Market Peers

3737.HK

Key Figures

PE Ratio (TTM)

7.25

Margin Of Safety (DCF)

98.56%

Revenue Growth (5 Year Average)

N/A

Ratings Consensus

Strong Buy

Share Buybacks

N/A

Dividend Yeild (TTM)

7.49%

Valuation

Value Score

67

  • Price-to-earnings ratio of 7.2 is lower than the market average (19.6x)
  • Free-cashflow-yeild of 8.78% is better than the market average (4.7%)
  • Margin-of-safety of 98.56% is better than the market average (17.95%)
  • Estimated intrinsic-value of 2.05 HKD is higher than current price ( 1.06 HKD)

Desired Margin Of Safety

0%

Tip: Set your desired Margin Of Safety

Free Cash Flow Type

Annual Cashflow Growth

0%

Discount Rate

0%

Buy Target: < 2 HKD

Current Price: 1 HKD

How Does This Work?

Show Advanced Options

This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.

Price/Earnings

7.25x

Free Cashflow Yeild

8.78%

PE/Earnings Growth

N/A

Price/Book

0.88x

Growth

Growth Score

20

  • Revenue growth has improved this yeara
  • Earnings growth has improved this year
  • Free Cashflow growth has improved this year
  • 5 Year Average Revenue growth of N/A is lower than the market average (10.97%)
  • 5 Year Average Earnings growth of N/A is lower than the market average (14.48%)
  • 5 Year Average Free Cashflow growth of N/A is lower than the market average (12.35%)

Revenue Growth

N/A

Earnings Growth

N/A

Cashflow Growth

N/A

Health

Health Score

45

  • Has a low level of debt
  • Assets cover liabilities
  • Low financial Leverage
  • Normal operation does not require debt to be sustainable
  • Debt repayments do not significantly impact cashflow

Altman Z Score

2.35

Piostroski Score

7.00

Debt/Equity

0.17x

Current Assets/Liabilities

1.82x

Free Cashflow/Total Debt

0.18x

Debt/Capital

0.15x

Dividend

Secure Dividend Score

55

  • Dividend yeild of 7.49% is more than the market average (1.85%)
  • Dividend is likely safe
  • Long term dividend payout ratio of 61.05% is considered good
  • Dividends have shown growth over the last 5 years
  • Spending a lower percentage of their income on dividends than last 5 years
  • Payout ratio (TTM) of 56.21% is higher than the average (40%)

Dividend Yeild

7.49%

Dividend Growth

N/A

Payout Ratio (Earnings)

56.21%

Payout Ratio (Cashflow)

85.30%

Management

Management Score

37

  • Has not bought shares or issued new shares in the last 5 years
  • Return-on-capital-employed of 4.21% is lower than the market average (10%)
  • Return-on-equity of 3.89% is lower than the market average (15%)

Average Buybacks/Dilution

N/A

Recent Buybacks/Dilution

3.63%

5 Year Price Volitility

9.41%

Return On Assets

2.32%

Return On Capital Employed

4.21%

Return On Equity

3.89%

Return On Free Cashflow

127.89%

Return On Investments

274.74%

Analysts

Analyst Opinion

86

  • Ratings consensus is Strong Buy

SEC Filings

Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.

Other Information

Company Name

Zhongzhi Pharmaceutical Holdings Limited

Currency

HKD

Beta

0.61098

Vol Avg

355919

Ceo

Cik

Cusip

G98961108

Exchange

HKSE

Full Time Employees

2849

Industry

Drug Manufacturers—Specialty & Generic

Sector

Healthcare

Ipo Date

2015-07-13

Address

No.3 Kangtai Road South, Torch Development Zone

City

Zhongshan

State

GUANGDONG

Country

CN

Zip

Phone

All financial data provided by FMP

Noticed an error with something on our site?

We Use Cookies